 |
|
Survival for Patients With Pancreatic Cancer After Addition of Gemcitabine to Fluorouracil Chemoradiation—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: In response to Dr Fujita and Dr Vikram, our study had 2 primary end points: survival for all patients and survival for patients with pancreatic head tumors. The median survival times for all eligible patients were 16.9 and 18.8 months for the chemoradiation plus fluorouracil and the chemoradiation plus gemcitabine treatment groups, respectively, as indicated in Figure 2. Stratification factors were chosen in 1997 when this trial was designed, based on data available then, and were accounted for in the multivariate analysis. Because the study was not powered to look for treatment differences within varying levels of stratification factors, including lymph node status, providing such results in the limited format of a letter reply could lead to misinterpretation. We will consider looking at the treatment effect within the stratification variables and reporting them completely in a future analysis.
A secondary analysis looking at lymph node ratio and its . . . [Full Text of this Article]
William F. Regine, MD
wregine@umm.edu
Department of Radiation Oncology
University of Maryland Medical Center
Baltimore
Kathryn A. Winter, MS
Radiation Therapy Oncology Group
Philadelphia, Pennsylvania
Howard Safran, MD
Division of Hematology-Oncology
Brown University
Providence, Rhode Island
RELATED LETTERS
Survival for Patients With Pancreatic Cancer After Addition of Gemcitabine to Fluorouracil Chemoradiation
Tetsuji Fujita
JAMA. 2008;299(24):2852.
EXTRACT
| FULL TEXT
Survival for Patients With Pancreatic Cancer After Addition of Gemcitabine to Fluorouracil Chemoradiation
Bhadrasain Vikram
JAMA. 2008;299(24):2852.
EXTRACT
| FULL TEXT
|
